secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-07-22T20:05:15+00:00
Accession:  0001193125-26-312390
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam COO Douglas Kling resigns to become CEO of another biotech; transition expected
--------------------------------------------------------------------------------

- Douglas Kling notified resignation as COO effective August 14, 2026.
- Kling will become CEO of another clinical-stage biotech company.
- Company expects separation agreement and advisor agreement for transition services.
- Advisor role will focus on PREVAIL clinical trial of obicetrapib and other programs.
- No replacement for COO announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/0001193125-26-312390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-312390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer